Matthews DR, Marre M, Le-Thi TD, et al
The possibilities are endless
Taspoglutide (a long acting GLP-1 agonist) was not found to have significant anti-atheromatous effects, although it did reduce hepatic triglyceride levels, suggesting an indirect mode of action [97]
If you are considering Semaglutide GLP-1 for weight loss, you should first consult with your primary care physician
Favorable Metabolic Effects GLP-1R agonists has shown to reduce the effects of several atherosclerotic cardiovascular disease (ASCVD) metabolic risk factors including diabetes mellitus, hyperlipidemia, overweight and obesity, and hepatic steatosis [68]
Additionally, in basic research, future studies could establish mouse models of obesity and diabetes and compare them with normal mice to exclude the interference of metabolic factors